Investigating alpha-synuclein changes as an early indicator of neurodegenerative diseases
Changes in synaptic vesicle-binding of alpha-synuclein as an early biomarker for synucleinopathies
['FUNDING_R01'] · WEILL MEDICAL COLL OF CORNELL UNIV · NIH-11049709
This study is looking at how changes in a protein called alpha-synuclein might help us spot early signs of neurodegenerative diseases like Parkinson's and Alzheimer's, so we can diagnose and help people sooner, even before they show any symptoms.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WEILL MEDICAL COLL OF CORNELL UNIV (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-11049709 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding how changes in the binding of alpha-synuclein to synaptic vesicles can serve as an early biomarker for neurodegenerative diseases like Parkinson's disease and Alzheimer's-related dementias. By examining both the brain and the enteric nervous system, the study aims to identify specific changes that occur before the onset of noticeable symptoms. The researchers will utilize biochemical analyses to explore these changes, potentially leading to earlier diagnosis and intervention for affected individuals.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals at risk for Parkinson's disease or Alzheimer's-related dementias, particularly those experiencing early symptoms such as gastrointestinal issues.
Not a fit: Patients with established neurodegenerative diseases who are already diagnosed may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could enable earlier detection and treatment of neurodegenerative diseases, improving patient outcomes.
How similar studies have performed: Previous research has shown promise in identifying biomarkers for neurodegenerative diseases, suggesting that this approach could yield valuable insights.
Where this research is happening
NEW YORK, UNITED STATES
- WEILL MEDICAL COLL OF CORNELL UNIV — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BURRE, JACQUELINE — WEILL MEDICAL COLL OF CORNELL UNIV
- Study coordinator: BURRE, JACQUELINE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer's disease and related dementia